Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.44 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383866 | 0.93 | TRPV1 (0.51) | TRPV1P2RY12KIT | |
| SCHEMBL12251233 | 0.92 | TRPV1 (0.41) | TRPV1NR2E1P2RY12NPSR1HSD17B10 | |
| SCHEMBL2383360 | 0.86 | TRPV1 (0.52) | TRPV1NR2E1NPSR1HSD17B10KIT | |
| SCHEMBL2384912 | 0.83 | TRPV1 (0.49) | TRPV1NR2E1NPSR1HSD17B10KIT | |
| SCHEMBL2382772 | 0.83 | TRPV1 (0.49) | TRPV1NR2E1NPSR1HSD17B10KIT | |
| SCHEMBL2384974 | 0.80 | TRPV1 (0.57) | TRPV1NPSR1HSD17B10 | |
| SCHEMBL2386175 | 0.80 | TRPV1 (0.47) | TRPV1NR2E1NPSR1KIT | |
| SCHEMBL2385592 | 0.78 | TRPV1 (0.55) | TRPV1NPSR1HSD17B10KIT | |
| SCHEMBL2386439 | 0.78 | TRPV1 (0.49) | TRPV1NR2E1NPSR1HSD17B10KIT | |
| SCHEMBL2384211 | 0.77 | TRPV1 (0.56) | TRPV1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | TRPV1 4108/4885NR2E1 2125/4885P2RY12 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.